Source:http://linkedlifedata.com/resource/pubmed/id/17483064
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2007-5-7
|
| pubmed:abstractText |
We investigated the feasibility of reduced-intensity conditioning with 4 Gy total body irradiation, fludarabine (30 mg/m2 for 6 days), and busulfan (4 mg/kg for 2 days) for bone marrow transplantation from a serologically HLA-matched unrelated donor. Seventeen adult patients (median age, 55 years; range, 27-67 years) with various hematologic malignancies (6 in remission, 11 not in remission) were treated. Successful engraftment was achieved in all patients at a median of day 18 (range, day 14-35) after transplantation, although subsequent secondary graft failure was observed in 2 patients. The cumulative incidence of acute graft-versus-host disease (GVHD) of grades II to IV at day 100 was 48%. With a median follow-up of 286 days (range, 56-687 days), the rates of 1-year overall survival, 100-day nonrelapse mortality, and 1-year nonrelapse mortality were 41%, 14%, and 46%, respectively. Eleven patients died, and the causes of death were relapse (n = 4), pulmonary complications (n = 4), acute GVHD (n = 2), and sepsis (n = 1). The remaining 6 patients (at transplantation, 2 were in remission, and 4 were not in remission) are currently still in remission. These results suggest that this regimen reduces the risk of graft failure, but further studies are needed to ameliorate transplantation-related toxicities, primarily GVHD and/or pulmonary complications.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0925-5710
|
| pubmed:author |
pubmed-author:AkahaneDaigoD,
pubmed-author:FukudaTakahiroT,
pubmed-author:HeikeYujiY,
pubmed-author:KimSung-WonSW,
pubmed-author:KusumotoShigeruS,
pubmed-author:MoriShin-ichiroS,
pubmed-author:Morita-HoshiYurikoY,
pubmed-author:OnishiYasushiY,
pubmed-author:SugimotoKyokoK,
pubmed-author:TakaueYoichiY,
pubmed-author:TanosakiRyujiR,
pubmed-author:TobinaiKenseiK
|
| pubmed:issnType |
Print
|
| pubmed:volume |
85
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
256-63
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:17483064-Adult,
pubmed-meshheading:17483064-Aged,
pubmed-meshheading:17483064-Bone Marrow Transplantation,
pubmed-meshheading:17483064-Busulfan,
pubmed-meshheading:17483064-Female,
pubmed-meshheading:17483064-Graft Survival,
pubmed-meshheading:17483064-Graft vs Host Disease,
pubmed-meshheading:17483064-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:17483064-Humans,
pubmed-meshheading:17483064-Japan,
pubmed-meshheading:17483064-Kaplan-Meier Estimate,
pubmed-meshheading:17483064-Male,
pubmed-meshheading:17483064-Middle Aged,
pubmed-meshheading:17483064-Myeloablative Agonists,
pubmed-meshheading:17483064-Retrospective Studies,
pubmed-meshheading:17483064-Transplantation, Homologous,
pubmed-meshheading:17483064-Transplantation Conditioning,
pubmed-meshheading:17483064-Vidarabine,
pubmed-meshheading:17483064-Whole-Body Irradiation
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation.
|
| pubmed:affiliation |
Division of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
|
| pubmed:publicationType |
Journal Article
|